サンプル依頼リスト カート
  • English
  • Korean
表紙：間質性肺疾患の世界市場レポート 2024年
市場調査レポート
商品コード
1415766

間質性肺疾患の世界市場レポート 2024年

Interstitial Lung Disease Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
間質性肺疾患の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

間質性肺疾患の市場規模は近年力強く成長しています。2023年の18億3,000万米ドルから2024年には19億7,000万米ドルへ、CAGR7.3％で拡大します。実績期間の成長は、認知度と診断の向上、免疫系調整療法、呼吸リハビリテーションプログラム、集学的ケアチームによるものと考えられます。

間質性肺疾患市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR7.4％で26億2,000万米ドルに成長します。予測期間の成長は、精密医療、新薬開発、再生医療、遠隔医療、遠隔モニタリングに起因します。予測期間の主要動向には、画像技術の進歩、画像診断におけるai、線維症サブタイプの鑑別、支持療法サービスが含まれます。

アレルギー疾患の蔓延拡大は、今後の間質性肺疾患市場成長の原動力になると予測されます。アレルギー疾患は、免疫系がアレルゲン（多くの場合、無害な物質）に過剰に反応することで発生します。こうしたアレルギー反応は、間質性肺疾患（ILD）、特に体内のアレルギー反応によって引き起こされる過敏性肺炎につながる可能性があります。例えば、2023年1月現在、米国の連邦公衆衛生機関である疾病対策予防センター（CDC）は、2021年には米国成人の3分の1以上、米国小児の4分の1以上が季節性アレルギー、湿疹、食物アレルギーを経験していると報告しています。さらに、アナフィラキシーとして知られる食物に対する重篤なアレルギー反応は、米国で年間9万件の救急外来を訪れると推定されました。したがって、アレルギー疾患の有病率の増加は、間質性肺疾患市場の成長の重要な促進要因となっています。

自己免疫疾患の罹患率の増加は、間質性肺疾患市場の拡大を当面促進します。自己免疫疾患とは、免疫システムが誤って身体の健康な組織や細胞を標的にする病状を指します。自己免疫疾患の症例の増加は、ILDに関連する医療サービスの需要を増大させ、研究開発のイニシアチブを促進し、治療と患者ケアの進歩を促進することによって、間質性肺疾患市場で重要な役割を果たしています。例えば、2023年9月、米国を拠点とする世界ヘルス研究センターであるInstitute for Health Metrics and Evaluationは、世界の関節リウマチの症例数が2020年の約1,760万人から2050年には約3,170万人に増加すると予測しました。今後数十年間における患者数の大幅な増加は、自己免疫疾患の罹患率が増加していることを裏付けています。その結果、自己免疫疾患の有病率の増加は、間質性肺疾患市場の成長の主要な促進要因となっています。

2023年の間質性肺疾患市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域と予想されています。間質性肺疾患レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の間質性肺疾患市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の間質性肺疾患の市場規模実績と成長率、2018～2023年
  • 世界の間質性肺疾患市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の間質性肺疾患市場、薬剤タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 経口コルチコステロイド
  • 免疫抑制
  • 抗線維化薬
  • その他
  • 世界の間質性肺疾患市場、疾患タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 間質性肺炎
  • 特発性肺線維症
  • 非特異的間質性肺炎
  • 過敏性肺炎
  • 原因不明の組織性肺炎（COP）
  • サルコイドーシス
  • 急性間質性肺炎
  • 世界の間質性肺疾患市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 成人
  • 小児
  • 世界の間質性肺疾患市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域と国の分析

  • 世界の間質性肺疾患市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界の間質性肺疾患市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 間質性肺疾患市場の競合情勢
  • 間質性肺疾患市場企業プロファイル
    • Roche Laboratories Inc.
    • Merck &Co. Inc.
    • Bayer AG
    • Novartis Pharmaceuticals Corporation
    • The Bristol-Myers Squibb Company

第31章 その他の主要と革新的な企業

  • Amgen Inc.
  • Boehringer Ingelheim
  • Siemens Healthineers
  • Koninklijke Philips N.V.
  • Teva Pharmaceuticals USA Inc.
  • AstraZeneca plc
  • Horizon Pharma USA Inc.
  • Genentech Inc.
  • Amneal Pharmaceuticals LLC
  • Fujirebio Diagnostics Inc.
  • Insmed Inc.
  • VIDA Diagnostics Inc.
  • EmphyCorp Inc.
  • Verseau Therapeutics
  • Regend Therapeutics Co.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r12365

“Interstitial Lung Disease Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on interstitial lung disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for interstitial lung disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The interstitial lung disease market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Oral Corticosteroids; Immune Suppressing; Anti-Fibrotic Medication; Other Drugs
  • 2) By Disease Type: Interstitial Pneumonia; Idiopathic Pulmonary Fibrosis; Nonspecific Interstitial Pneumonitis; Hypersensitivity Pneumonitis; Cryptogenic Organizing Pneumonia (COP); Sarcoidosis; Acute Interstitial Pneumonitis
  • 3) By Application: Adults; Children
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Roche Laboratories Inc.; Merck & Co. Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; The Bristol-Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Interstitial lung disease (ILD) refers to a group of lung conditions that affect the interstitium, the tissue and space surrounding the alveoli in the lungs. The interstitium is crucial for maintaining the structural integrity and function of the lungs, facilitating the exchange of gases between the lungs and the bloodstream.

The primary types of drugs used in the treatment of interstitial lung disease include oral corticosteroids, immunosuppressive medications, anti-fibrotic drugs, and others. Interstitial pneumonia, also referred to as non-infectious interstitial pneumonia, is a specific type of interstitial lung disease (ILD) that affects the interstitium, the tissue supporting the air sacs (alveoli) in the lungs. These drugs are indicated for the treatment of various ILD conditions, including interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis in both adults and children. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The interstitial lung disease market research report is one of a series of new reports from The Business Research Company that provides interstitial lung disease market statistics, including interstitial lung disease industry global market size, regional shares, competitors with an interstitial lung disease market share, detailed interstitial lung disease market segments, market trends and opportunities and any further data you may need to thrive in the interstitial lung disease industry. This interstitial lung disease market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interstitial lung disease market size has grown strongly in recent years. It will grow from $1.83 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to awareness and diagnosis improvement, immune system modulation therapies, respiratory rehabilitation programs, multidisciplinary care teams.

The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to precision medicine, novel drug development, regenerative medicine, telehealth and remote monitoring. Major trends in the forecast period include advancements in imaging technology, ai in imaging, fibrosis subtype differentiation, supportive care services.

The expansion in the prevalence of allergic conditions is anticipated to be a driving force behind the growth of the interstitial lung disease market in the future. Allergic conditions occur when the immune system reacts excessively to allergens, often harmless substances. These allergic reactions can lead to interstitial lung disease (ILD), specifically hypersensitivity pneumonitis, which is triggered by an allergic response within the body. For instance, as of January 2023, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported that in 2021, over one-third of American adults and more than one-fourth of American children experienced seasonal allergies, eczema, or food allergies. Additionally, severe allergic reactions to food, known as anaphylaxis, were estimated to result in 90,000 emergency room visits in the United States annually. Hence, the growing prevalence of allergic conditions is a significant driver of the interstitial lung disease market's growth.

The increasing incidence of autoimmune ailments is set to propel the expansion of the interstitial lung disease market in the foreseeable future. Autoimmune ailments refer to medical conditions where the immune system mistakenly targets the body's healthy tissues and cells. The rise in autoimmune ailment cases plays a crucial role in the interstitial lung disease market by augmenting the demand for healthcare services related to ILD, spurring research and development initiatives, and fostering advancements in treatments and patient care. For instance, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research center, projected that the global cases of rheumatoid arthritis would increase from around 17.6 million in 2020 to approximately 31.7 million by 2050. This substantial rise in cases over the coming decades underscores the growing incidence of autoimmune ailments. Consequently, the increasing prevalence of autoimmune ailments is a key driver of the interstitial lung disease market's growth.

The growth of the interstitial lung disease market is hindered by delayed diagnoses during the forecast period. Delayed diagnosis of interstitial lung disease (ILD) poses significant challenges to patients as it raises the risk of complications and has psychosocial impacts, ultimately leading to increased healthcare costs. For example, in 2021, the British Thoracic Society, a UK-based charitable organization, reported substantial delays between the onset of ILD symptoms and the actual diagnosis, with approximately 40% of patients enduring waiting periods exceeding two years before receiving a formal diagnosis. Consequently, delayed diagnosis has impeded the progress of the interstitial lung disease market.

Major companies operating in the interstitial lung disease market are committed to developing innovative drugs to provide effective treatment options and maintain their market standing. The development of new drugs holds the potential to improve treatment outcomes for patients with lung-related conditions. For instance, in April 2021, United Therapeutics, a US-based biotechnology company, introduced Tyvaso, a medication designed to enhance exercise capacity in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso is a sterile form of the prostacyclin-mimicking drug treprostinil, specifically designed for oral inhalation using the Tyvaso inhalation system.

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. This strategic acquisition is aimed at strengthening Merck & Co.'s immunology drug pipeline as it faces the looming loss of exclusivity for some of its top-selling products in the coming years. Prometheus Biosciences Inc., a US-based biotechnology company, specializes in developing therapeutic and complementary diagnostic products for the management of immune-mediated disorders, including interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD).

Major players in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc .

North America was the largest region in the interstitial lung disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the interstitial lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Interstitial Lung Disease Market Characteristics

3. Interstitial Lung Disease Market Trends And Strategies

4. Interstitial Lung Disease Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Interstitial Lung Disease Market Size and Growth

  • 5.1. Global Interstitial Lung Disease Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Interstitial Lung Disease Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Interstitial Lung Disease Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Interstitial Lung Disease Market Segmentation

  • 6.1. Global Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral Corticosteroids
  • Immune Suppressing
  • Anti-Fibrotic Medication
  • Other Drugs
  • 6.2. Global Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Interstitial Pneumonia
  • Idiopathic Pulmonary Fibrosis
  • Nonspecific Interstitial Pneumonitis
  • Hypersensitivity Pneumonitis
  • Cryptogenic Organizing Pneumonia (COP)
  • Sarcoidosis
  • Acute Interstitial Pneumonitis
  • 6.3. Global Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Adults
  • Children
  • 6.4. Global Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Interstitial Lung Disease Market Regional And Country Analysis

  • 7.1. Global Interstitial Lung Disease Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Interstitial Lung Disease Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Interstitial Lung Disease Market

  • 8.1. Asia-Pacific Interstitial Lung Disease Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Interstitial Lung Disease Market

  • 9.1. China Interstitial Lung Disease Market Overview
  • 9.2. China Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Interstitial Lung Disease Market

  • 10.1. India Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Interstitial Lung Disease Market

  • 11.1. Japan Interstitial Lung Disease Market Overview
  • 11.2. Japan Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Interstitial Lung Disease Market

  • 12.1. Australia Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Interstitial Lung Disease Market

  • 13.1. Indonesia Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Interstitial Lung Disease Market

  • 14.1. South Korea Interstitial Lung Disease Market Overview
  • 14.2. South Korea Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Interstitial Lung Disease Market

  • 15.1. Western Europe Interstitial Lung Disease Market Overview
  • 15.2. Western Europe Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Interstitial Lung Disease Market

  • 16.1. UK Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Interstitial Lung Disease Market

  • 17.1. Germany Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Interstitial Lung Disease Market

  • 18.1. France Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Interstitial Lung Disease Market

  • 19.1. Italy Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Interstitial Lung Disease Market

  • 20.1. Spain Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Interstitial Lung Disease Market

  • 21.1. Eastern Europe Interstitial Lung Disease Market Overview
  • 21.2. Eastern Europe Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Interstitial Lung Disease Market

  • 22.1. Russia Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Interstitial Lung Disease Market

  • 23.1. North America Interstitial Lung Disease Market Overview
  • 23.2. North America Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Interstitial Lung Disease Market

  • 24.1. USA Interstitial Lung Disease Market Overview
  • 24.2. USA Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Interstitial Lung Disease Market

  • 25.1. Canada Interstitial Lung Disease Market Overview
  • 25.2. Canada Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Interstitial Lung Disease Market

  • 26.1. South America Interstitial Lung Disease Market Overview
  • 26.2. South America Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Interstitial Lung Disease Market

  • 27.1. Brazil Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Interstitial Lung Disease Market

  • 28.1. Middle East Interstitial Lung Disease Market Overview
  • 28.2. Middle East Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Interstitial Lung Disease Market

  • 29.1. Africa Interstitial Lung Disease Market Overview
  • 29.2. Africa Interstitial Lung Disease Market, Segmentation By Drug Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Interstitial Lung Disease Market Competitive Landscape And Company Profiles

  • 30.1. Interstitial Lung Disease Market Competitive Landscape
  • 30.2. Interstitial Lung Disease Market Company Profiles
    • 30.2.1. Roche Laboratories Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis Pharmaceuticals Corporation
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. The Bristol-Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Interstitial Lung Disease Market Other Major And Innovative Companies

  • 31.1. Amgen Inc.
  • 31.2. Boehringer Ingelheim
  • 31.3. Siemens Healthineers
  • 31.4. Koninklijke Philips N.V.
  • 31.5. Teva Pharmaceuticals USA Inc.
  • 31.6. AstraZeneca plc
  • 31.7. Horizon Pharma USA Inc.
  • 31.8. Genentech Inc.
  • 31.9. Amneal Pharmaceuticals LLC
  • 31.10. Fujirebio Diagnostics Inc.
  • 31.11. Insmed Inc.
  • 31.12. VIDA Diagnostics Inc.
  • 31.13. EmphyCorp Inc.
  • 31.14. Verseau Therapeutics
  • 31.15. Regend Therapeutics Co.

32. Global Interstitial Lung Disease Market Competitive Benchmarking

33. Global Interstitial Lung Disease Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Interstitial Lung Disease Market

35. Interstitial Lung Disease Market Future Outlook and Potential Analysis

  • 35.1 Interstitial Lung Disease Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Interstitial Lung Disease Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Interstitial Lung Disease Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer